Jonathan Chernoff


Name:  Jonathan Chernoff, M.D., Ph.D.
Address:  Fox Chase Cancer Center
                     333 Cottman Avenue, W455
                     Philadelphia, PA 19111
Phone: (215) 728-5319
Fax:       (215) 728-3616
Lab website:

1984 - M.D, Ph.D.    Mount Sinai School of Medicine (Medical Scientist Training Program (Discipline: Biochemistry)
1978 - B.A.                  Yale College (Discipline: Molecular Biophysics & Biochemistry)
2021 - present         Cancer Center Director, Senior Vice President, Fox Chase Cancer Center; Senior Associate Dean for Cancer Research Programs, Lewis Katz School of Medicine at Temple University
2010 - 2021             Scientific Director, Senior Vice President, Deputy Cancer Center Director, Fox Chase Cancer Center
2008 - 2010             Vice President, Deputy Scientific Director, Fox Chase Cancer Center
2008 - present         Stanley P. Reimann Chair in Oncology Research, Fox Chase Cancer Center
2004 - present         Adjunct Professor, Drexel University School of Medicine
2002 - present         Professor (senior member), Fox Chase Cancer Center
1999 - present         Co-Director, Cancer Biology Program, Fox Chase Cancer Center
1996 - present         Adjunct Assistant Professor, University of Pennsylvania
1996 - 2002             Associate Professor (member w/tenure), Fox Chase Cancer Center
1991 - 1996             Assistant Professor (associate member), Fox Chase Cancer Center
1988 - 1991             Postdoctoral Fellow (Erikson lab), Department of Cellular & Developmental Biology, Harvard University
1988 - 1990             Clinical Fellow, Hematology/Oncology Department, Beth Israel Hospital
1987 - 1988             Clinical Fellow, Department of Medical Oncology, The Johns Hopkins Oncology Center
1984 - 1987             Resident, Department of Internal Medicine, University Health Center of Pittsburgh
2023                         Associate Fellow, Branford College, Yale University    
2021 - present     FWO Review College (Belgium)
2019 - 2021            Selection Committee, AACR Outstanding Investigator Award in Breast Cancer Research
2018                         Co-Chair, AACR Annual Meeting Program Committee
2017                         Fellow, American Association for the Advancement of Science (AAAS)
2017                         Chairperson AACR Gertrude B. Elion Cancer Research Grant Scientific Review Committee
2016                         Co-Organizer, Celebrating AKT Symposium
2016                         Senior Faculty Award, 4th Annual Temple Translational Science Symposium
2016 - 2022          Member, Interurban Clinical Club
2014                         AACR, Educational Session Leader
2013                         Pennsylvania Drug Discovery Institute, Drug Discovery Award
2011 - 2012            Chair: NF2 Preclinical Consortium
2010                         ACS Scientific Research Award, Southeast PA Region
2010                         Russian Academy of Science, Conference on Gene Expression, session leader
2010                         NF Conference, session leader
2008 - 2011           Senior Fellow, American Asthma Association
2008 - present    Member, The Kinome Virtual Academy of the Targeted Proteins Database
2007                        Dozer Lecturer, Ben Gurion University
2005 - present   Member, Faculty of 1000
2007                        Chair, Gordon Conference “Mechanisms of Cell Signaling”
2006                        Vice Chair, FASEB “Small G Protein Networks in Cell Dynamics”     
2005                        Vice Chair, Gordon Conference “Mechanisms of Cell Signaling”
1997 - 2002          Leukemia Society of America (Scholar)
1993 - 1998           American Cancer Society Research Scholar
1993 - 1996           W.W. Smith Charitable Trust Fellowship
1996                         Pfizer Traveling Fellow Award
American Board of Internal Medicine
Subspecialty Board – Medical Oncology
Medical License – Pennsylvania
U.S. Patent 11,240,996 B2 “Mice with transgene of iBox peptide inhibitor of Group B p21-activated kinases”

(~282, H index = 65 (Web of Science); = 81 (Google Scholar))
1.         Chernoff, J., Li, H.C., Cheng, Y.S.E. and Chen, L.B. Characterization of a phosphotyrosyl protein phosphatase activity associated with a phosphoseryl protein phosphatase of Mr = 95,000 from bovine heart. J. Biol. Chem. 258:7852, 1983.
2.         Chernoff, J. and Li, H.C. Multiple forms of phosphotyrosyl- and phosphoseryl-protein phosphatase from cardiac muscle: partial purification and characterization of an EDTA stimulated phosphotyrosyl-protein phosphatase. Arch. Biochem. Biophys. 226:517, 1983.
3.         Li, H.C., Chernoff, J., Chen, L.B. and Kirschonbaum, A. A phosphotyrosyl protein phosphatase activity associated with acid phosphatase from human prostate gland. Eur. J. Biochem. 138:45, 1984.
4.         Chernoff, J., Sells, M.A. and Li, H.C. Characterization of phosphotyrosyl protein phosphatase activity associated with calcineurin. Biochem. Biophys. Res. Comm. 121:141, 1984.
5.         Sells, M.A., Chernoff, J., Cerda, A., Bowers, C., Shafritz, D.A., Kase, N., Christman, J.K.
and Acs, G. Long-term culture and passage of human fetal liver cells that synthesize albumin. In Vitro Cell. Dev. Biol. 21:216, 1985.
6.         Chernoff, J. and Li, H.C. A major phosphotyrosyl-protein phosphatase from bovine heart is associated with a low-molecular-weight acid phosphatase. Arch. Biochem. Biophys. 240:135, 1985.
7.         Chernoff, J., Schievella, A.G., Jost, C.J., Erikson, R.L. and Neel, B.G. Cloning of the cDNA of a major human protein-tyrosine-phosphatase. Proc. Natl. Acad. Sci. USA 87:2735-2739, 1990.
8.         Ottilie, S., Chernoff, J., Hannig, G., Hoffman, C.S. and Erikson, R.L. A fission yeast gene encoding a protein with features of protein-tyrosine-phosphatases. Proc. Natl. Acad. Sci. USA 88: 3455-3459, 1991.
9.         Ottilie, S., Chernoff, J., Hannig, G., Hoffman, C.S. and Erikson, R.L. The fission yeast genes pyp1 and pyp2 encode protein tyrosine phosphatases that negatively regulate mitosis. Mol. Cell. Biol. 12:5571-5580, 1992.
10.      Patriotis, C., Makris, A., Chernoff, J., and Tsichlis, P.N. Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase. Proc. Natl. Acad. Sci. USA 91:9755, 1994.
11.      Sells, M.A. and Chernoff, J. Epitope-tagging vectors for eukaryotic protein production. Gene 152:187-189, 1995.
12.      Sells, M.A, Li, J. and Chernoff, J. Delivery of protein into cells using polycationic liposomes. BioTechniques 19:72-78, 1995.
13.      Knaus, U.G., Morris, S., Dong, H.-J., Chernoff, J., and Bokoch, G.M. Regulation of p21activated kinases through G protein-coupled receptors. Science 269:221-223, 1995.
14.      Creasy, C.L. and Chernoff, J. Cloning and characterization of a human protein kinase with homology to Ste20. J. Biol. Chem. 270:21695-21700, 1995.
15.      Bagrodia, S., Taylor, S., Creasy, C.L., Chernoff, J., and Cerione, R.A. Identification of a murine p21Cdc42/Rac activated kinase (PAK). J. Biol. Chem. 270:22731-22738, 1995.
16.      Zhang, S., Han, J., Sells, M.A., Chernoff, J., Knaus, U.G., Ulevitch, R.J., and Bokoch, G.M. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J. Biol. Chem. 270: 23934-23936, 1995.
17.      Vambutas, V., Kaplan, D.R., Sells, M.A., and Chernoff, J. NGF stimulates tyrosine phosphorylation and activation of SH-PTP1 in PC12 cells. J. Biol. Chem. 270: 2562925634, 1995.
18.      Creasy, C.L. and Chernoff, J. Cloning and characterization of a member of the MST subfamily of Ste20-like kinases. Gene 167: 303-306, 1995.
19.      Ottilie, S., Miller, P.J., Johnson, D.I., Creasy, C.L., Sells, M.A., Bagrodia, S., Forsburg,
S.L., and Chernoff, J. Fission yeast pak1+ encodes a protein kinase that interacts with Cdc42p and is involved in the control of cell polarity and mating. EMBO J. 14:5908-5919, 1995.
20.      Creasy, C.L., Ambrose, D.M., and Chernoff, J. The human Ste20-like kinase, Mst1, dimerizes and contains an inhibitory domain. J. Biol. Chem. 271:21049-21053, 1996.
21.      Galisteo, M.L., Chernoff, J., Su, Y.-C., Skolnik, E.Y., and Schlessinger, J. The adaptor protein Nck links receptor tyrosine kinases with the serine/threonine kinase Pak1. J. Biol. Chem. 271:20997-21000, 1996.
22.      Liu, F., Hill, D.E., and Chernoff, J. Direct binding of the proline rich region of Protein Tyrosine Phosphatase 1B to the Src homology 3 domain of p130Cas. J. Biol. Chem. 271:31290-31295, 1996.
23.      Bandyopadhyay, D., Kusari, A., Kenner, K., Liu, F., Chernoff, J., Gustafson, T.A., and Kusari, J. Protein Tyrosine Phosphatase 1B binds to the insulin receptor in vivo and is tyrosine phosphorylated in the presence of insulin. J. Biol. Chem. 272:1639-1645, 1997.
24.      Sells, M.A., Knaus, U.G., Bagrodia, S., Ambrose, D., Bokoch, G.M. and Chernoff, J.
Human p21-activated kinases (Paks) regulate actin reorganization in mammalian cells. Curr. Biol. 7:202-210, 1997.
25.      Tang, Y., Chen, Z., Ambrose, D., Liu, J., Gibbs, J.B., Chernoff, J., and Field, J. Kinase deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol. Cell. Biol. 17:4454-4464, 1997.
26.      Liu, F. and Chernoff, J. Protein tyrosine phosphatase 1B interacts with epidermal growth factor receptor in cultured cells. Biochem. J. 327:139-145, 1997.
27.      Liu, F., Sells, M.A., and Chernoff, J. Suppression of oncogene-mediated transformation of rat 3Y1 fibroblasts by protein tyrosine phosphatase 1B requires a functional SH3-ligand. Mol. Cell. Biol. 18:250-259, 1998.
28.      Liu, F., Sells, M.A., and Chernoff, J. Protein tyrosine phosphatase 1B negatively regulates integrin signaling. Curr. Biol. 8:173-176, 1998.
29.      Zhang, B., Chernoff, J., and Zheng, Y. Interaction of Rac1 with GTPases-activating proteins and putative effectors. J. Biol. Chem. 273:8776-8782, 1998.
30.      Graves, J.D., Gotoh, Y., Draves, K.E. Ambrose, D., Han, D.K.N., Wright, M., Chernoff, J., Clark, E.A., Krebs, E.G. Caspase-mediated cleavage and activation of the mammalian Ste20-like kinase Mst1 during apoptosis. EMBO J. 17:2224-2234, 1998.
31.      Sells, M.A., Barratt, J.T., Caviston, J., Ottilie, S., Leberer, E., and Chernoff, J.
Characterization of Pak2, a pleckstrin-homology-domain-containing p21-activated protein kinase from fission yeast. J. Biol. Chem. 273:18490-18498, 1998.
32.      Adam, L., Vadlamudi, R., Kondapaka, S.B., Chernoff, J., Mendelsohn, J., and Kumar, R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J. Biol. Chem. 273:28238-28246, 1998.
33.      Wardenburg, J.B., Pappu, R., Bu, J.-Y., Mayer, B., Chernoff, J., Straus, D., and Chan, A.C. Regulation of PAK activation and the T cell cytoskeleton by the linker protein SLP-76 Immunity, 9: 607-616, 1998.
34.      Sells, M.A., Boyd, J., and Chernoff, J. p21-activated kinase regulates motility in mammalian fibroblasts. J. Cell Biol. 145:837-849, 1999. (cover story)
35.      Adam L, Vadlamudi RK, Mandal M, Chernoff J, and Kumar R. p21-activated kinase-1 regulates microfilament reorganization and invasiveness of breast cancer cells. J. Biol. Chem, 275:12041-12050, 2000.
36.      Dadke, S, Kusari, J, and Chernoff, J. Down-regulation of insulin signaling by Protein Tyrosine Phosphatase (PTP) 1B is mediated by an N-terminal binding region. J. Biol. Chem. 275:23642-23647, 2000.
37.      Dharmawardhane, S., Schurmann, A., Sells, M.A., Chernoff, J., Schmid, S.L., and Bokoch, G.M. Regulation of macropinocytosis by p21-activated kinase-1. Mol. Biol. Cell 11:33413352, 2000.
38.      Vadlamudi, R.K., Ratna K., Adam, L., Wang, R.-A., Mandal, M., Nguyen, D., Sahin, A., Chernoff, J., Hung, M.-C., and Kumar, R. Regulatable expression of p21-activated kinase1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J. Biol. Chem. 275:36238-36244, 2000.
39.      Arora, V.K., Molina, R.P., Foster, J.L., Blakemore, J.L., Chernoff, J., Fredericksen, B.L., and Garcia, J.V. Lentiviral Nef specifically activates Pak2. J. Virol. 74:11081-11087, 2000.
40.      Sells, M.A., Pfaff, A., and Chernoff, J. Temporal and spatial distribution of activated Pak1 in fibroblasts. J. Cell Biol. 151:1449-1457, 2000.
41.      Mota, M. Reeder, M.K., Chernoff, J., and Bazenet, C.E. Evidence for a role of mixedlineage kinases in neuronal apoptosis. J. Neurosci. 21:4949-4957, 2001
42.      Reeder, M.K., Serebriiskii, I.G., Golemis E.A., and Chernoff, J. Analysis of small GTPase signaling pathways using Pak1 mutants that selectively couple to Cdc42. J. Biol. Chem. 276:40606-40613, 2001.
43.      Dadke, S. and Chernoff, J. Interaction of Protein-Tyrosine Phosphatase (PTP)1B with its substrates is influenced by two distinct binding domains. Biochem. J. 364:377-383, 2002.
44.      Thiel, D.A., Reeder, M.K., Pfaff, A., Coleman, T.R., Sells, M. A., and Chernoff, J. Cell cycle regulated phosphorylation of p21-activated kinase 1 (Pak1) Curr. Biol. 12:1227-1232, 2002. Recommended at F1000 Prime (
45.      Li, F., Adam, L., Vadlamudi, R.K., Zhou, H., Sen, S., Chernoff, J., Mandal, M.,and Kumar, R. p21-activated kinase 1 interacts with and phosphorylates Histone H3 in breast cancer cells. EMBO Reports 3:767-773, 2002.
46.      Astrinidis, A, Cash, T.P., Hunter, D.S., Walker, C.L., Chernoff, J., and Henske. E.P. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion, and migration. Oncogene 21:8470-8476, 2002.
47.      Serebriiskii, I.G., Mitina, O., Pugacheva, E., Benevolenskaya, E., Kotova, E., Toby, G.G., Khazak, V., Kaelin, W.G., Chernoff, J., and Golemis, E.A. Detection of peptides, proteins, and drugs that selectively interact with protein targets. Genome Res. 12:1785-1791, 2002.
48.      Penzes, P., Beeser, A., Chernoff, J., Schiller, M.R., Eipper, B.A., Mains, R.E., and Huganir, R.L. Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rac1-GEF kalirin. Neuron 37:263-274, 2003. Recommended at F1000 Prime (
49.      Cheung, W.L., Ajiro, K., Samejima, K., Kloc, M., Cheung, P., Mizzen, C.A., Beeser, A., Etkin, L.D., Chernoff, J., Earnshaw, W.C., and Allis, C.D. Apoptosis in vertebrates is characterized by phosphorylation of histone H2B mediated by Mammalian Sterile Twenty kinase Cell, 113:507–517, 2003.
50.      Deacon, K., Mistry, P., Chernoff, J., Blank, J.L., and Patel, R. p38 MAP kinase mediates cell death and p21-activated kinase (PAK) mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol. Biol. Cell 14:2071-2087, 2003.
51.      Cotteret, S., Jaffer, Z.M., Beeser, A. and Chernoff, J. p21-activated kinase-5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol. Cell. Biol., 23:5526-5539, 2003.
52.      Zegers, M.M.P., Forget, M.A., Chernoff, J., Mostov, K.E., ter Beest, M.B.A., and Hansen,
S.H. Pak1 and PIX regulate contact inhibition during epithelial wound healing. EMBO J.,
22:4155-4165. 2003. Recommended at F1000 Prime (
53.      Dadke, S. and Chernoff, J. Protein-tyrosine phosphatase 1B mediates the effects of insulin on the actin cytoskeleton in immortalized fibroblasts. J. Biol. Chem., 278:40607-40611, 2003.
54.      Cai, D., Iyer, A., Near, R.I., Felekkis, K.N., Luo, Z., Albanese, C., Peste, R.G., Chernoff, J., and Lerner, A. AND-34/BCAR3, a GDP exchange factor whose over-expression confes anti-estrogen resistance, activates Rac, PAK, and the cyclin D promoter. Cancer Res., 63:6802-6808, 2003.
55.      Reynolds, L.F., de Bettigniers, C., Norton, T., Beeser, A., Chernoff, J., and Tybulewicz, V.L.J. Vav1 transduces T cell receptor signals to the activation of the Ras/ERK pathway via LAT, Sos, and RasGRP1. J. Biol. Chem., 279:18239-18246, 2004.
56.      Parsons, M., Monypenny, J., Ameer-Beg, S.M., Millard, T.H., Machesky, L.M., Peter, M., Keppler, M.D., Schiavo, G., Watson, R., Chernoff, J., Zicha, D., Vojnovic, B., Ng, T.
Spatially Distinct Binding of Cdc42 to PAK1 and N-WASP in Breast Carcinoma Cells. Mol. Cell. Biol., 25:1680-1695, 2005.
57.      Gonzalez Guerrico, A.M., Jaffer, Z.M., Page, R.E., Braunewell, K.-H., Chernoff, J., and Klein-Szanto, A.J.P. Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cells. Oncogene, 24:2307-2316, 2005.
58.      Leisner, T.M., Liu, M., Jaffer, Z.M., Chernoff, J., Parise, L.V. Essential role of CIB1 in regulating PAK1 activation and cell migration. J. Cell Biol., 170:465-476, 2005.
59.      Beeser, A., Jaffer, Z.M., Hofmann, C., and Chernoff, J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J. Biol. Chem., 280:36609-36615, 2005.
60.      Li, S., Depetris, R., Barford, D., Chernoff, J., and Hubbard, S.R. Crystal structure of protein tyrosine phosphatase 1B bound to the insulin receptor tyrosine kinase. Structure, 13:1643-
1651, 2005. Recommended at F1000 Prime (
61.      Bartholomew, P.J., Jones, C.W., Benware, A., Hanks, S., Chernoff, J., and LaFlamme, S.E. Regulation of the catalytic activity of PTP1B: roles for cell adhesion, tyrosine residue 66, and proline residues 309 and 310. Exp. Cell Res., 311:294-306, 2005.
62.      Cotteret, S. and Chernoff, J. Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic properties. Mol. Cell Biol., 26:3215-3230, 2006.
63.      ten Klooster, J.P., Jaffer, Z.M., Chernoff, J., and Hordijk, P.L. Targeting and activation of Rac1 are mediated by the exchange factor b-Pix. J. Cell Biol., 172:759-769, 2006.
64.      Pirruccello, M., Sondermann, H., Pelton, J.G., Pellicena, P., Hoelz, A., Chernoff, J., Wemmer, D.E., and Kuriyan, J. Dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases. J. Mol. Biol., 361:312-326, 2006.
65.      Thullberg, M., Gad, A., Beeser, A., Chernoff, J., and Strömblad, S. The kinase-inhibitory domain of p21-activated kinase 1 (PAK1) inhibits cell cycle progression independent of PAK1 kinase activity. Oncogene, 26:1820-1828, 2007.
66.      Dadke, S., Cotteret, S., Yip, S.-C., Jaffer, Z.M., Haj, F., Ivanov A., Rauscher III, F., Shuai, K., Ng, T., Neel, B.G., and Chernoff, J. Regulation of Protein-Tyrosine Phosphatase (PTP) 1B by sumoylation Nat. Cell Biol. 9:80-85, 2007.
67.      Rennefahrt, U.E.E., Deacon, S., Parker, S.A., Devarajan, K., Beeser, A., Chernoff, J., Knapp, S., Turk, B.E., and Peterson, J.R., Comprehensive specificity profiling of Pak kinases allows identification of novel phosphorylation sites. J. Biol. Chem. 282:1566715678, 2007.
68.      Friedland, J.C., Lakins, J.N., Kazanietz, M.G., Chernoff, J., Boettiger, D., and Weaver, V.M. α6β4 integrin activates Rac-dependent p21-activated kinase 1 to drive NFêBdependent apoptosis resistance in 3D mammary acini. J. Cell Sci. 120:3700-3712, 2007.
69.      Mao, K., Kobayashi, S., Jaffer, Z.M., Huang, Y., Volden, P., Chernoff, J., and Liang, Q.
Regulation of Akt/PKB activity by p21-activated kinase in cardiomyocytes. J. Mol. Cell. Cardiol. 44:429-434, 2008.
70.      Deacon, S.W., Beeser, A., Fukui, J.A., Rennefahrt, U.E.E., Myers, C., Chernoff, J., and Peterson, J. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem. Biol., 15:322-331, 2008. (Deacon and Beeser, co-first authors).
71.      McDaniel, A.S, Allen, J.D., Park, S.-J., Michels, E.G., Burgin, S.J., Chen, S., Bessler, W.K., Chernoff, J., and Clapp, D.W*. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-infunction phenotypes in Nf1+/- mast cells. Blood 112:4646-4654, 2008.
72.      Smith S.D., Jaffer, Z.M., Chernoff, J., and Ridley, A.J. PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamics. J. Cell Sci. 121:3729-3736, 2008.
73.      Allen, J.D., Jaffer, Z.M., Burgin, S., Hofmann, C., Sells, M.A., Derr-Yellin, E., Michels,
E.G., Bessler, W.K., Ingram, D.A., Chernoff, J.*, and Clapp, D.W.* p21-activated kinase 1
is required in mast cells for FceRI-mediated inflammatory responses. Blood. 113:26952705, 2009. *co-corresponding authors. (Allen and Jaffer, co-first authors, Chernoff and Clapp co-senior authors).
74.      Van den Broeke, C., Radu, M., Deruelle, M., Nauwynck, H., Hofmann, C., Jaffer, Z.M., Chernoff, J. and Favoreel, H.W. Alpha-herpesvirus US3-mediated reorganization of the actin cytoskeleton is mediated by p21-activated kinases 1 and 2. Proc. Natl. Acad. Sci. 106:8707-8712, 2009.
75.      Arias-Romero, L.E., Saha, S., Villamar, O., Yip, S.-C., Ethier, S.P., Zhang, Z-Y., and Chernoff, J. Activation of Src by Protein Tyrosine Phosphatase (PTP)1B is required for ErbB2 transformation of breast epithelial cells. Cancer Res. 69:4582-4588, 2009.
76.      Flaiz, C., Chernoff, J. Ammoun, S., Peterson, J.R., and Hanemann, C.R. PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp. Neurology 218:137-144, 2009.
77.      Lightcap, C.M., Kari, G., Arias-Romero, L.E., Chernoff, J., Rodeck, U., and Williams, J.C. Interaction with LC8 Is required for Pak1 nuclear import and is indispensable for Zebrafish development. PLoS ONE 4:e6025, 2009.
78.      Menges, C., Chen, Y., Mossman, B., Chernoff, J., Yeung, A., and Testa, J.R. A Phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in Malignant Mesothelioma. Genes & Cancer 1:493-505, 2010.
79.      Arias-Romero, L., Villamar-Cruz, O., Pacheco, A., Kosoff, R., Huang, M., Muthuswamy, S., and Chernoff, J. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene 29:5839-5849, 2010.
80.      Molli, P.R., Li, D.Q., Bagheri-Yarmand, R., Pakala, S.B., Katayama, H., Sen, S., Iyer, J., Chernoff, J., Tsai, M.Y., Nair, S.S., and Kumar, R. Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J. Cell Biol. 190:101-114, 2010.
81.      Chow, H.-Y., Stepanova, D., Koch, J., and Chernoff, J. p21-activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. PLoS ONE 5:e13791, 2010. doi:10.1371/ journal.pone.0013791.
82.      Makhlin, I., Zhang, J., Chernoff, J., and Boorjian, S. The mTOR pathway impacts proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. Brit. J. Urol. 108:E84-90, 2011.
83.      Van den Broeke, C., Radu, M., Nauwynck, H.J., Chernoff, J., Favoreel, H.W. Role of group A p21-activated kinases in the anti-apoptotic activity of the pseudorabies virus US3 protein kinase. Virus Res. 155:376-380, 2011.
84.      De La Mota-Peynado, A., Chernoff, J, and Beeser A. Identification of the atypical extracellular regulated kinase 3 (Erk3) as a novel substrate for p21-activated kinase (Pak) activity. J. Biol. Chem. 286:13603-13611, 2011.
85.      Shepelev, M.V., Chernoff, J., and Korobko, I. Rho Family GTPase Chp/RhoV induces PC12 apoptotic cell Death via JNK activation. Small GTPases 2:17-26, 2011.
86.      Delorme-Walker, V.D., Peterson, J.R., Chernoff, J., Waterman, C.M., Danuser, G., Dermardirossian, C., Bokoch, G.M. Pak1 regulates focal adhesion strength, myosin IIA distribution, and actin dynamics to optimize cell migration. J. Cell Biol. 193:1289-1303, 2011. Recommended at F1000 Prime (
87.      Sela, M., Bogin, Y., Beach, D., Oellerich, T., Lehne, J., Smith-Garvin, J., Okumura, M., Starosvetsky, E., Kosoff, R., Libman, E., Koretzky, G.A., Kambayashi, T., Urlaub, H., Wienands, J., Chernoff, J., and Yablonski, D. Sequential phosphorylation of SLP-76 at tyrosine 173 is required for activation of T and Mast cells. EMBO J. 30:3160-3172, 2011.
88.      Li, A., Ma, Y., Mort, R.L., Lindsay, C., Stevenson, D., Strathdee, D., Insall, R.H., Chernoff, J., Snapper, S.B. Jackson, I.J., Larue, L., Sansom, O.J., and Machesky, L.M. Rac1 drives melanoblast organization during mouse development by orchestrating pseudopod-driven motility and cell cycle progression. Dev. Cell 21:722-734, 2011.
89.      Wang, X., Oh, E., Clapp, D.W., Chernoff, J., and Thurmond„ D.C. Inhibition or ablation of p21-activated kinase (PAK1) disrupts glucose homeostatic mechanisms in vivo. J. Biol. Chem. 286:41359-41367, 2011.
90.      Taglieri, D.M., Monasky, M.M., Knezevic, I, Sheehan, K.A., Lei, M., Wang X., Chernoff, J., Wolska, B.M., Ke, Y., and Solaro, R.J. Ablation of p21-activated kinase in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2. J. Mol. Cell Cardiol. 51:988-996, 2011.
91.      Yip, S.C., Cotteret, S., and Chernoff, J. Sumoylated Protein Tyrosine Phosphatase (PTP)1B localizes to the inner nuclear membrane and regulates the tyrosine phosphorylation of emerin. J. Cell Sci. 125:310-316, 2012.
92.      Monasky, M.M., Taglieri, D.M., Patel, B.G., Chernoff, J., Wolska, B.M., Ke, Y., and Solaro, R.J. p21-activated kinase improves myocardial performance during ischemia/reperfusion injury by modulation of Troponin-T and Myosin Light Chain 2 phosphorylation. Am. J. Physiol. 302:H224-230, 2012.
93.      Hoover, W.C., Zhang, W., Xue, Z., Gao, H., Chernoff, J., Clapp, D.W., Gunst, S.J., and Tepper, R.S. Inhibition of p21-activated kinase (PAK) reduces airway responsiveness in vivo and in vitro in murine and human airways. PLoS One 7:e42601, 2012.
94.      Jhaveri, K.A., Debnath, P., Chernoff, J., Sanders, J., and Schwartz, M.A. The role of p21activated kinase in the initiation of atherosclerosis. BMC Cardiovascular Disorders 12:5562, 2012.
95.      Menges, C.W., Sementino, E., Talarchek, J., Xu, J., Chernoff, J., Peterson, J.R., and Testa, J.R.  Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol. Cancer Res. 10:1178-1188, 2012.
96.      Chow, H.Y., Jubb, A.M., Koch, J.N., Jaffer, Z.M., Stepanova, D., Campbell, D.A., Duron, S. G., O’Farrell, M., Cai, Q., Klein-Szanto, A.J., Gutkind, J.S., Hoeflich, K.P., and Chernoff, J. p21-activated kinase 1 is required for efficient tumor formation and progression in a Rasmediated skin cancer model. Cancer Res. 72:5966-5975, 2012.
97.      Chiang, Y.A., Shao, W., Chernoff, J., and Jin, T. p21-activated protein kinase 1 (Pak1) mediates the crosstalk between insulin and β-catenin on proglucagon gene expression and its ablation affects glucose homeostasis. Endocrinology 154:77-88, 2013.
98.      Kosoff, R., Chow, H.Y., Radu, M., and Chernoff, J. Pak2 restrains mast cell FcεRIsignaling through modulation of Rho GEF activity. J. Biol. Chem. 288:974-983, 2013.
99.      Radu, M. and Chernoff, J. An in vivo assay to test blood vessel permeability. J. Vis. Exp. 16:e50062, 2013.
100.   Dorrance, A.M., De Vita, S., Radu, M., Reddy, P.N.G., McGuinness, M.K., Harris, C.E., Mathieu, R., Lane, S.W., Kosoff, R., Milsom, M.D., Chernoff, J.,* and Williams, D.A. * The Rac GTPase effector p21 Activated Kinase-2 is essential for hematopoietic stem/progenitor cell migration and engraftment. Blood 121:2474-82, 2013 *(co-senior authors)
101.   Huynh, N., Yim, M., Chernoff, J., Shulkes, A., Baldwin, G.S., and He, H. p21-activated kinase 1 mediates gastrin-stimulated proliferation of the colorectal mucosa via multiple signalling pathways. Am J Physiol. Gastrointest. Liver Physiol. 304:G561-7, 2013.
102.   Rawat, S., Creasy, C.L., Peterson, J., and Chernoff, J. The tumor suppressor Mst1 promotes changes in the cellular redox state by phosphorylating and inactivating peroxiredoxin-1. J. Biol. Chem. 288:8762-71, 2013.
103.   Arias-Romero, L. E., Villamar-Cruz, O., Huang, M., Hoeflich, K.P., and Chernoff, J. p21activated kinase-1 links ErbB2 to β-catenin in transformation of breast epithelial cells. Cancer Res., 73:3671-82, 2013.
104.   Aslan, J., Itakura, A., Haley, K., Tormoen, G., Loren, C., Baker, S., Pang, J., Chernoff, J., and McCarty, O.J.T. PAK signaling coordinates GPVI-mediated platelet aggregation, lamellipodia formation and aggregate stability under shear. Arterioscler. Throm. Vasc. Biol. 33:1544-51, 2013.
105.   Aslan, J.E., Baker, S.M., Loren, C.P., Haley, K.M., Itakura, A., Pang, J., Greenberg, D.L., David, L.L., Chernoff, J., Manser, E., and McCarty, O.J.T. The PAK system links Rho GTPase signaling to thrombin-mediated platelet activation. Am. J. Physiol. Cell Physiol. 305:C519-28, 2013.
106.   Radu, M., Rawat, S.J., Beeser, A. and Chernoff, J. ArhGAP15, a Rac-specific GTPase Activating Protein, plays a dual role in inhibiting small GTPase signaling. J. Biol. Chem. 288:21117-25. 2013.
107.   Itakura A., Aslan, J.E., Kusanto, B.T., Phillips, K.G., Porter, J.E., Newton, P.K., Nan, X., Insall, R.H, Chernoff, J., and McCarty O.J. p21-activated kinase (PAK) regulates cytoskeletal reorganization and directional migration in human neutrophils. PLoS One 8:e73063, 2013.
108.   Licciulli, S., Maksimoska, J., Zhou, C., Troutman, S., Kota, S., Lin, Q., Duron, S., Campbell, D., Chernoff, J., Field, J., Mamorstein, R., and Kissil, J.L. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of NF2-associated schwannomas. J. Biol. Chem. 288:29105-14, 2013.
109.   Chiang, Y.A., Ip, W., Shao, W., Song, Z.E., Chernoff, J., and Jin, T. Activation of GLP-1 signaling attenuates impaired hepatic glucose disposal in aged male p21-activated protein kinase-1 knockout mice. Endocrinology 155:2122-32, 2014.
110.   Kelly, M.L., Astsaturov, A., Rhodes, J., and Chernoff, J. A Pak1/Erk signaling circuit acts through Gata6 to regulate cardiovascular development in zebrafish. Dev. Cell 29:350-9, 2014.
111.   Phee, H., Au-Yeung, B.B., Pryshchep, O., O’Hagan, K.L., Fairbairn, S.G., Radu, M., Kosoff, R., Mollenauer, M., Cheng, D., Chernoff, J., and Weiss, A. Pak2 is required for actin cytoskeleton remodeling, TCR signaling, and normal thymocyte development and maturation. Elife 3:e02270, 2014.
112.   Elsherif, L., Ozler, M., Zayed, M.A., Shen, J.H., Chernoff, J., Faber, J.E., and Parise, L.V. Potential compensation among group I PAK members in hindlimb ischemia and wound healing. PLoS One 9:e112239, 2014.  
113.   Badolia, R., Manne, B.K., Dangelmaier, C., Chernoff, J., and Kunapuli, S.P. Gq-mediated Akt translocation to the membrane: a novel PIP3-independent mechanism in platelets. Blood 125:175-84, 2015.
114.   Zeng, Y., Broxmeyer, H.E., Staser, K., Chitteti, B.R., Park, S.J., Hahn, S., Cooper, S., Sun,
Z., Jiang, L., Yang, X., Yuan, J., Kosoff, R., Sandusky, G., Srour E.F., Chernoff J., and Clapp D.W. Pak2 regulates hematopoietic progenitor cell proliferation, survival and differentiation. Stem Cells 33:1630-41, 2015.
115.   Chow, H.Y., Dong, B., Duron, S.G., Campbell, D., Ong, C.C., Hoeflich, K.P., Chang, L.S., Welling, D.B., Yang, Z.j., and Chernoff, J. Group I Paks as therapeutic targets in NF2deficient meningioma. Oncotarget 10:1981-1994, 2015.
116.   Ong, C.C., Gierke, S., Pitt, C., Sagolla, M., Cheng, C.K., Zhou, W., Jubb, A.M., Strickland,
L., Schmidt, M., Duron, S.G., Campbell, D.A., Zheng, W., Dehdashti, S., Shen, M., Yang,
N., Behnke, M.L., Huang, W., McKew, J.C., Chernoff, J., Forrest, W., Haverty, P.M., Chin, S.-F., Rakha, E.A., Green, A.R., Ellis, I.O., Caldas, C., O’Brien, T., Friedman, L.S., Koeppen, H., Rudolph, J., and Hoeflich, K.P. Small molecule inhibition of group I PAKs in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Res. 17:59, 2015.
117.   Singh, N. K., Kotla, S., Dyukova, E., Traylor, J.G. Jr. Orr, A.W., Chernoff, J. Marion, T.N., Rao, G.N. Disruption of p21-activated kinase 1 gene diminishes atherosclerosis in apolipoprotein E-deficient mice. Nat. Comm. 6:7450, 2015.
118.   O’Hagan, K.L., Choi, J., Pryshchep, O., Chernoff, J., and Phee, H. Pak2 Links TCR Signaling Strength to the Development of Regulatory T Cells and Maintains Peripheral Tolerance, J. Immunol. 195:1564-1577, 2015.
119.   Kosoff„ R.E., Aslan, J.E., Kostyak, J.C., Dulaimi, E., Chow, H.-Y., Prudnikova, T.Y., Radu, M., Kunapuli, S.P., McCarty, O.J.T., and Chernoff, J. Pak2 restrains endomitosis during megakaryopoiesis. Blood 125:2995-3005, 2015.
120.   Pandolfi, A., Stanley, R.F., Bartholdy, B., Pendurti, G., Gritsman, K., Boultwood, J., Chernoff, JH., Verma, A., and Steidl, U. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood 126:1118-1127, 2015.
121.   Radu, M., Lyle, K., Hoeflich, K.P., Villamar-Cruz, O., Koeppen, H., and Chernoff, J. p21activated kinase 2 (Pak2) regulates endothelial development and function through Bmk1/Erk5 pathway. Mol. Cell. Biol. 35:3990-2005, 2015 (cover story).
122.   Prudnikova, T,Y., Villamar-Cruz, O., Rawat, S.J., Cai, K.Q., and Chernoff J. Effects of p21activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene 35:21782185, 2016.
123.   Reddy, P.N.G., Radu, M., Xu, K., Wood, J., Harris, C.E., Chernoff, J., and Williams, D.A.
p21 activated kinase 2 regulates HSC cytoskeleton, migration and homing via CDC42 activation and interaction with b-Pix. Blood, 127:1967-1975, 2016.
124.   Rawat, S.J., Araiza-Olivera, D., Arias-Romero, L.E., Villamar-Cruz, O., Prudnikova, T.Y., Roder, H., and Chernoff, J. H-ras inhibits the hippo pathway by promoting Mst1/Mst2 heterodimerization. Curr. Biol. 26:1556–1563, 2016. (Featured as “Editor’s Choice,” Sci.
Signaling 9:ec154, 2016; Recommended at F1000 Prime (
125.   Kurimchak, A.M., Shelton, C., Duncan, K.E., Johnson, K., Brown, J., Shane O’Brien, S., Gabbasov, R., Fink, L., Li, Y.S., Childers, W.E., Connolly, D.C., Chernoff, J., Peterson, J.R.
and Duncan, J.S. Adaptation of the kinome promotes resistance to BET bromodomain inhibitors in ovarian cancer. Cell Rep. 16:1273-1286, 2016 (Featured as “Research Highlight,” Nature Rev. Clin. Oncol. 19 Aug 2016; doi:10.1038/nrclinonc.2016.130).
126.   Hu, B., Arpag, S., Zhang, X., Mobius, W., Werner, H., Sosinsky, G., Ellisman, M., Zhang, Y., Hamilton, A., Chernoff, J., and Li, J. Tuning PAK Activity to Rescue Abnormal Myelin Permeability in HNPP. PLoS Genet. 12:e1006290, 2016.   
127.   Villamar-Cruz, O., Prudnikova, T., Araiza-Olivera, D., Pérez-Plasencia, C., Johnson, N.,
Bernhardy, A., Slifker, M., Renner, C., Chernoff, J., and Arias-Romero, L. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition, Oncotarget 7:76590-76603, 2016.
128.   Prudnikova, T. and Chernoff, J. The Group I Pak inhibitor Frax-1036 sensitizes 11q13amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases, 8:193198, 2017.
129.   Joseph, G.A., Lu, M., Radu, M., Lee, J., Burden, S.J., Chernoff, J., and Krauss, R.S. Group I Paks promote skeletal myoblast differentiation in vivo and in vitro. Mol. Cell. Biol. 37: e00222-16, 2017.
130.   Semenova, G., Stepanova, D., Deyev, S.M., and Chernoff, J. Medium throughput biochemical compound screening identified novel agents for pharmacotherapy of neurofibromatosis type I. Biochimie 135:1-5, 2017.
131.   Semenova, G., Stepanova, D., Dubyk, C., Handorf, E., Deyev, S.M., Lazar, A.J., and Chernoff, J. Targeting Group I p21-activated kinases to control tumor growth and metastasis in malignant peripheral nerve sheath tumors. Oncogene 36:5421-5431, 2017.
132.   Stepanova, D.S., Semenova, G., Kuo, Y.-M., Andrews, A.J., Ammoun, S., Hanemann, C.O., and Chernoff, J. A novel function of the tumor suppressor gene NF2: Merlin controls fatty acid synthesis levels. Cancer Res. 77:5026-5038, 2017.
133.   Tan, Y., Sementino, E., Chernoff, J., and Testa, J.R. Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity. Am. J. Cancer Res. 7:17241737, 2017.
134.   Lu, H., Liu, S., Zhang, G., Wu, B., Zhu, Y., Frederick, D.T., Hu, Y., Zhong, W., Randell, S., Sadek, N., Zhang, W., Chen, G., Cheng, C., Zeng, J., Wu, L.W., Zhang, J., Liu, X., Xu, W.,
Krepler, C., Sproesser, K., Xiao, M., Miao, B., Liu, J., Song, C.D., Liu, J.Y., Karakousis,
G.C., Schuchter, L.M., Lu, Y., Mills, G., Cong, Y., Chernoff, J., Guo, J., Boland, G.M.,
Sullivan, R.J., Wei, Z., Field, J., Amaravadi, R.K., Flaherty, K.T., Herlyn, M., Xu, X., and Guo, W. PAK signaling drives acquired drug resistance to MAPK inhibitors in BRAF mutant melanomas. Nature 550:133-136, 2017. (N.B., author correction published Nature, 2019, 565(7738):E4. doi: 10.1038/s41586-018-0814-7)
135.   Zeng, K., Tian, L., Sirek, A., Shao, W., Liu, L., Chiang, Y.T., Chernoff, J., Ng, D.S., Weng, J., and Jin, T. Pak1 mediates the stimulatory effect of insulin and curcumin on hepatic ChREBP expression. J. Mol. Cell Biol. 9:384-394, 2017.
136.   Zeng, Y., Hahn, S., Stokes, J.L., Hoffman, E.A., Chernoff, J., and Katsanis, E. Pak2 regulates myeloid derived suppressor cell development in mice. Blood Adv. 1:1923-1933, 2017.
137.   Araiza-Olivera, D., Feng, Y., Semenova, G., Prudnikova, T., Rhodes, J., and Chernoff, J. Suppression of RAC1-driven malignant melanoma by Group A PAK inhibitors. Oncogene 37:944-952, 2018.
138.   Kim, S., Ravi, A., Nguyen, T., Kubiniok, P., Finicle, B., Malacrida, L., Hou, J., Jayashankar, V., Robertson, J., Chernoff, J., Digman, M., Potma, E., Tromberg, B., Thibault, P., and Edinger, A. PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells. Cancer Discovery 8:866-883, 2018.
139.   Chow, H.Y., Dong, B., Valencia, C.A., Zeng, C.T., Koch, J.N., Prudnikova, T.Y. and Chernoff, J. Group I Paks are essential for epithelial-mesenchymal transition in an Apc driven model of colorectal cancer. Nature Comm. 9:3437, 2018.
140.   Karchugina, S. and Chernoff, J. Detection of heterodimerization of protein isoforms using an in situ proximity ligation assay. J. Vis. Exp. doi:10.3791/57755, 2018.
141.   Binder, P., Wang, S., Radu, M., Zin, M., Collins, L., Khan, S., Li, Y., Sekeres, K., Humphreys, N., Swanton, E., Reid, A., Pu, F., Oceandy, D., Guan, K., Hille, S.S., Frey, N., Müller, O.J., Cartwright, E.J., Chernoff, J., Wang., X., and Liu, W. Pak2 as a novel therapeutic target for cardioprotective endoplasmic reticulum stress response. Circ. Res. 124:696-711, 2019.
142.   Korobeynikov, V., Borakove, M., Feng, Y., Wuest, W.M., Koval, A., Nikonova, A.N., Serebriiskii, I., Chernoff, J., Borges, V.F., Golemis, E.A., and Shagisultanova, E. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. Breast Cancer Res. Treat. 177:369-382, 2019.
143.   Kurimchak, A., Shelton, C., Duncan, K., Chernoff, J., Herrera-Montávez, and Duncan J. Intrinsic Resistance to MEK Inhibition Through BET protein mediated kinome reprogramming in NF1-deficient ovarian cancer. Mol. Cancer Res. 17:1721-1734, 2019.
144.   Shen, Y.C., Arellano-Garcia, C., Menjivar, R., Jewett, E.M., Dohle, W., Karchugina, S., Chernoff, J., Potter, B.V.L., and Barald, K.F. Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2). BMC Pharmacol. Toxicol. 20:67, 2019.
145.   Sannai, M., Doneddu, V., Giri, V., Seeholzer, S., Nicolas, E., Yip, S.-C., Mancuso, P., Bassi, M., Cortellino, S., Cigliano, A., Lurie, R., Ding, H., Chernoff, J., Sobol, R., Yen, T., Bagella, L., and Bellacosa, A. Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1. DNA Repair 82:102687, 2019.
146.   Uribe-Alvarez, C., Guerrero-Rodríguez, S.L., Rhodes, J., Cannon, A., Chernoff*, J., and Araiza-Olivera*, D. Targeting effector pathways in RAC1P29S-driven malignant melanoma. Small GTPases 17:1-9, 2020. *co-corresponding authors
147.   Kurimchak, A. M., Herrera-Montavez, C., Brown, J., Johnson, K.J., Sodi, V., Srivastava,
N., Kumar, V., Deihimi, S., O’Brien, S., Peri, S., Mantia-Smaldone, G.M., Jain, A., Winters, R.M., Cai, Q., Chernoff, J., Connolly, D.C., and Duncan, J.S. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma Sci. Signal. 13: eaax8238, 2020.
148.   Hawley, E.T., Gehlhausen, J.R., Karchugina, S., Chow, H.-Y., Araiza-Olivera, D., Radu, M., Smith, A.B., Burks, C.A., Jang, L., Li, X., Masters, A.R., Edwards, D., Burgin, C., Jones, D., Bessler, W.K., Yates, C.W., Clapp, D.W*., Chernoff*, J., and Su-Jung, P. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2). Hum. Mol. Genetics 30:1607-1617, 2021. *co-corresponding authors.
149.   Uribe-Alvarez, C., Lam, Q., Baldwin, D.A. and Chernoff, J. Low saliva pH can yield false Positive Result In simple RT-LAMP-based Sars-Cov-2 diagnostic tests. PLoS One 16:e0250202, 2021.
150.   Kaur, N., Ruiz-Velasco, A., Raja, R., Howell, G., Miller, J.M., Riham R. E. Abouleisa, R.E., Ou, Q., Mace, K., Hille, S.S., Frey, N., Binder, P., Smith, C.P., Fachim, H., Soran, H., Swanton, E., Mohamed, T.M.A., Müller, O.J., Wang, X., Chernoff, J., Cartwright, E.J., and Liu, W. Paracrine signal emanating from stressed cardiomyocytes aggravates inflammatory microenvironment in diabetic cardiomyopathy. iScience 25:103973, 2022.
151.   Binder, P., Nguyen, B., Collins, L., Zi, M., Liu, W., Christou, F., Luo, X., Hille, S.S., Frey, N., Cartwright, E.J., Chernoff, J., Müller, O.J., Guan, K., and Wang, X. Pak2 regulation of Nrf2 serves as a novel signalling nexus linking ER stress response and 1 oxidative stress in the heart. Frontiers Cardiovascular Med. 9:851419, 2022.
152.   Sementino, E., Kadariya, Y., Cheung, M., Menges, C., Tan, Y.F., Kukuyan, A.-M., Shrestha, U., Karchugina, S., Cai, K., Peri, S., Duncan, J., Chernoff, J., and Testa, J.R. Inactivation of p21-activated kinase 2 inhibits development of Nf2-deficient Tumors by restricting hedgehog and Wnt signaling. Mol. Cancer Res. 20:699, 2022.
153.   Kathania, M., Kumar, R., Lenou, E., Basrur, V., Chernoff, J., Thiess, A.L., and Venuprasad, K. Pak2-mediated phosphorylation promotes RORgt ubiquitination and inhibits colonic inflammation. Cell Reports 40:111345, 2022.
154.   Saldivar-Cerón, H.I., Villamar-Cruz, O. Wells, C.M., Chernoff, J., Patino-Lopez, G., Huerta-Yepez, S., Montecillo-Aguado, M., Rivera-Pazos, C.M., Loza-Mejía, M.A., Vivar-Sierra, A., Briseño-Díaz, P., Zentella-Dehesa, A., Leon-Del-Rio, A., López-Saavedra, A., Padierna-Mota, L., de Jesús Ibarra-Sánchez, M., Esparza-López, L., Hernandez Rivas, R., and Arias-Romero, L.E. p21-Activated kinase 1 promotes breast tumorigenesis via phosphorylation and activation of the calcium/calmodulin-dependent protein kinase II Pak1 activates CaMKII signaling in breast cancer Front. Cell Dev. Bio. 9:759259, 2022.
155.   Chow, H.-Y., Karchugina, S, Groendyke, B., Toenjes, S, Hatcher, J., Donovan, K., Fischer, E., Abalakov, G., F, B., Dunbrack, R., Gray, N., and Chernoff, J. Development and utility of a PAK1-selective degrader. J. Med. Chem.  65:15627–15641, 2022.
156.   Wang, Y., Risteski, P.,Yang. Y., Chen, H., Droby, G., Ariel, P., Walens, A., Troester, M., Herring, L., Chernoff, J., Tolić, I.M., Bowser1, J., and Vaziri, C. TRIM69-STK3 signaling axis regulates centrosome dynamics and cancer cell survival (submitted).
157.   Hu, B., Moiseev, D., Schena, I., Chernoff, J., and Li, J. PAK2 is Necessary for Myelination in the Peripheral Nerve System (submitted).
1.         Chernoff, J., Schievella, A.R., and Neel, B.G. Molecular cloning and expression of a major human protein tyrosine phosphatase. Adv. Protein Phosphatases 6:59-71, 1991.
2.         Sells, M.A. and Chernoff, J. Polymerase chain reaction cloning of related genes. Meth. Enzymol. 254:184-195, 1995.
3.         Sells, M.A. and Chernoff, J. Emerging from the Pak: the p21-activated protein kinase family. Trends Cell Biol. 7:162-167, 1997.
4.         Chernoff, J. Protein tyrosine phosphatases as negative regulators of mitogenic signaling. J. Cell. Physiol. 180:173-181, 1999.
5.         Chernoff, J. Close encounters of the LIM kinase. Nature Cell Biol. 1:E115-117, 1999.
6.         Valster, A.H., Hepler, P.K., and Chernoff J. Plant GTPases: the Rhos in bloom. Trends Cell Biol, 10:141-146, 2000.
7.         Chernoff, J. Mitogenic signal transduction, in Basic Science of Cancer, Current Medicine (Kruh, G.D and Tew, K.D., eds) 75-92, 2000.
8.         Serebriiskii, I.G., Mitina, O.V., Chernoff, J., and Golemis, E.A. Use of a two-hybrid dual bait system to discriminate specificity of protein interactions in small GTPases. Meth. Enzymol. 332:277-300, 2001.
9.         Cotteret, S. and Chernoff, J. The evolutionary history of effectors downstream of Cdc42 and Rac. Genome Biology 3: 0002.1-0002.8, 2002. (cover story)
10.      Chernoff, J. Signal Transduction and Mammalian Cell Growth, in Protein-Protein Interactions: A Molecular Cloning Manual, CSHL Press (Golemis, E.A., ed) 7-13, 2002.
11.      Jaffer, Z and Chernoff, J. p21-activated kinases: three more join the Pak. Int J. Biochem. & Cell Biol. 34:713-717, 2002.
12.      Nikolic, M. and Chernoff, J. High midsummer for Rho GTPases. Trends Cell Biol. 12:495497, 2002.
13.      Dadke, S. and Chernoff, J. Protein-Tyrosine Phosphatase 1B as a potential drug target for obesity. Curr. Drug Targets – Immune, Endocr. & Metabol. Disord. 3:243-248, 2003.
14.      Beeser, A and Chernoff, J. Rho GTPases and Cell Motility, in Rho GTPases, Landes Biosciences publs (Symons, M., ed) 141-154, 2003. ISBN: 1-58706-199-6, epub
15.      Valster, A.H., Hepler, P.K., and Chernoff, J. Rho GTPases in plants, in Rho GTPases, Landes Biosciences publs (Symons, M., ed) 219-229, 2003. ISBN: 1-58706-199-6, epub
16.      Xiao, G.-H., Chernoff, J,. and Testa, J.R. NF2: The wizardry of Merlin. Genes Chrom. Cancer 38:389-399, 2003.
17.      Jaffer, Z. and Chernoff, J. The cross Rho’ds of cell-cell adhesion. J. Biol. Chem.
279:35123-35126, 2004.
18.      Hofmann, C., Shepelev, M., and Chernoff, J. The genetics of Pak. J. Cell. Sci. 117:43434354, 2004.
19.      Sorokina, E. and Chernoff, J. Rho GTPases: new members, new pathways. J. Cell. Biochem. 94:225-231, 2005.
20.      Golemis, E.A. and Chernoff, J. Editorial: Analysis and manipulation of intracellular signaling cascades. Methods, 32/4:347-348, 2005.
21.      Chernoff J. STK4 (serine/threonine kinase 4). Atlas Genet. Cytogenet. Oncol. Haematol.
November 2005. URL:
22.      Cotteret, S. and Chernoff, J. Pak GITs to Aurora A. Dev. Cell. 9:1–2, 2005.
23.      Beeser, A and Chernoff, J. Production and use of a cell permeable inhibitor of group A Paks (TAT-PID) to analyze signal transduction. Methods 37:203-207, 2005.
24.      Peterson, J.R. and Chernoff, J. Src transforms in a Cool way. Nat. Cell Biol. 8:905-907, 2006.
25.      Chernoff, J. Pak5. UCSD-Nature Molecule Pages (2007). (doi:10.1038/mp.a000829.01).
26.      Chernoff, J. PTP1B. UCSD-Nature Molecule Pages (2008). (doi:10.1038/mp.a000088.01).
27.      Chernoff, J. Mst1. UCSD-Nature Molecule Pages (2008). (doi:10.1038/mp.a001348.01).
28.      Chernoff, J. Mst2. UCSD-Nature Molecule Pages (2008). (doi:10.1038/mp.a001347.01).
29.      Stepanova, D. and Chernoff J. PAK1 (p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast)). Atlas Genet Cytogenet Oncol Haematol. December 2007.
30.      URL:
31.      Arias-Romero L.E. and Chernoff, J. A tale of two Paks. Biology of the Cell 100:97-108, 2008.
32.      Radu, M. and Chernoff, J. The deMSTification of Mammalian Sterile-20 Kinases. Curr. Biol. 19:R421-R425, 2009.
33.      Pacheco, A. and Chernoff, J. Group I p21-Activated kinases: emerging roles in immune function and viral pathogenesis. Int J. Biochem. & Cell Biol. 42:13-16, 2010.
34.      Van den Broeke, C., Radu, M., Chernoff, J., and Favoreel, H. An emerging role for p21activated kinases (Paks) in viral infections. Trends Cell Biol. 20:160-169, 2010.
35.      Cerione, R., Chernoff, J., Kahn, R.A., Knaus, U. Gary M. Bokoch (1954–2010), Dev. Cell 18: 357-358, 2010.
36.      Yip, S.C., Saha, S., and Chernoff, J. Protein Tyrosine Phosphatase 1B: a cellular double agent in metabolism and oncogenesis. Trends Biochem. 35:442-449, 2010.
37.      Kosoff, R. and Chernoff, J. LOV conquers (sm)all GTPases. F1000 Biology Reports, 2:28 doi:10.3410/B2-28, 2010.
38.      Arias-Romero, L. and Chernoff, J. p21-activated kinases in ErbB2-positive breast cancer: a new therapeutic target? Small GTPases 1:124-128, 2010.
39.      Huson, S.M., Acosta, M.T., Belzberg, A., Bernards, A., Chernoff, J., Cichowski, K., Evans,
D.G., Ferner, R.E., Giovannini, M., Korf, B., Listernick, R., North, K., Packer, R., Parada, L.F., Peltonen, J., Ramesh, V., Reilly, K., Schorry, E., Uphadyaya, M., Viskochil, D., Zhu,
Y., Hunter-Schaedle, K., Giancotti, F. Conference Report: Back to the Future: Proceedings from the 2010 NF Conference. Am. J Med. Gen. 155:307-321, 2010.
40.      Arias-Romero, L.E. and Chernoff J. p21-activated kinases in Erbb2-positive breast cancer: A new therapeutic target? Small GTPases 1:124-128, 2010.
41.      Kelly, M.L. and Chernoff, J. Getting smart about p21-activated kinases. Mol. Cell Biol. 31:386-387, 2011.
42.      Semenova, G. and Chernoff, J. PKM2 enters the morpheein academy. Mol. Cell. 45:583584, 2012.
43.      Kelly, M.L. and Chernoff, J. Mouse models of Pak function. Cell Logist. 2:84-88, 2012.
44.      Kelly, M.L., Astsaturov, A., and Chernoff, J. Role of p21-activated kinases in cardiovascular development and function. Cell Mol Life Sci 70:4223-4228, 2013.
45.      Arias-Romero, L.E. and Chernoff, J. Targeting Cdc42 in cancer. Exp Op. Ther. Targ. 17:1263, 2013.
46.      Hoeflich, K.P., Rudolph, J., Crawford, J., and Chernoff, J. Small molecule inhibitors of Pak. The Enzymes 34:157-180, 2013.
47.      Saha, S. and Chernoff, J. Analysis of PTP1B sumoylation. Methods, 65:201-206, 2014.
48.      Radu, M., Semenova, G., Kosoff, R., and Chernoff, J. PAK signalling during the development and progression of cancer. Nat. Rev. Cancer 14:13-25, 2014.
49.      Baker, N.M., Yee Chow, H., Chernoff, J, and Der, C.J. Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers. Clin. Cancer Res. 20:4740-6. 2014.
50.      Prudnikova, T.Y., Rawat, S.J., and Chernoff, J. Molecular pathways: targeting the kinase effectors of RHO-family GTPases. Clin. Cancer Res. 21:24-9, 2015.
51.      Rawat, S.J. and Chernoff, J. Regulation of mammalian Ste20 (Mst) kinases. Trends Biochem. Sci. 40:149-56, 2015.
52.      Wells, G., Chernoff, J., Gilligan J.P., and Krause, D.S. Does salmon calcitonin cause cancer: a review and meta-analysis. Osteoporos. Int. 27:13-9, 2016.
53.      Chernoff, J. Rac1. Cancer Therapeutic Targets (Springer New York, J.L. Marshall ed.) 1-5, 2016, doi:10.1007/978-1-4614-6613-0_24-2.
54.      Bellacosa, A., Chernoff, J., and Testa, J.R. Alfred G. Knudson (1922–2016), Cell 166: 785786, 2016.
55.      Araiza-Olivera, D. and Chernoff, J. Hras helps Hippo heterodimerize to evade tumor suppression, Small GTPases, doi: 10.1080/21541248.2016.1228794, 2016.
56.      Semenova, G. and Chernoff, J. Targeting PAK1. Biochem. Soc. Trans. 45:79-88, 2017.
57.      Chernoff, J. Alfred G. Knudson: in Memorium (1922-2106). Cancer Res. 77:815-816, 2017.
58.      Radu, M. and Chernoff, J. Recent advances in methods to assess the activity of the kinome. F1000Research, 6:1004, 2017.
59.      Stepanova, D.S. and Chernoff, J. A new concept in NF2 pharmacotherapy: targeting fatty acid synthesis, Oncoscience 5:126-127, 2018.
60.      Chernoff, J. How to get and keep your lab funded. Mol. Biol. Cell 29:2519-2521, 2018.
61.      Chernoff, J. What is my paper really worth? Mol. Biol. Cell 30:2878-2879, 2019.
62.      Benton, D. and Chernoff, J. A new Rho(d)-map to diffuse gastric cancer. Cancer Discov. 10:182-184, 2020.
63.      Cannon, A., Uribe-Alvarez, C., and Chernoff, J. The emerging roles of Rac1 in cancer. Trends Cancer 6:478-488, 2020.
64.      Budagyan, K. and Chernoff, J., Ras isoform signaling analysis. Methods Mol. Biol. (in press).
65.      Chernoff, J. 2020 in 20/20 hindsight. Mol. Biol. Cell 32:1007-1008, 2021.
66.      Karguchina, S., Benton, D., and Chernoff, J. Regulation of MST complexes and activity via SARAH domain modifications. Biochem. Soc. Trans. 49:675-683, 2021.
67.      Chernoff, J. The two-hit theory hits fifty. Mol. Biol. Cell 32: 2021,
68.      Chernoff, J. (Obituary) Beatrice Mintz, PhD, pioneering researcher at Fox Chase, dies at 100. The Cancer Letter 48, No. 01, January 07, 2022.
69.      Skalka, A.M. and Chernoff, J. Beatrice Mintz: In Memoriam. Cancer Res. 82:739–740, 2022.
70.      Chernoff, J. The Institutes for Cancer Research Murderer’s Row. The Cancer Letter 48, No. 20, May 20, 2022.
71.      Chernoff, J. Getting back to where we once belonged. The Cancer Letter 48, No. 31, August 5, 2022.
72.      Payaningal S.R., Chernoff, J., Cummings, B.S., Prasad, S.M., and Homan, H.D. Targeting p21-activated kinase-1 for metastatic prostate cancer. Cancers 15, 2236-, 2023.
Golemis E.A. and Chernoff, J. Editors, Analysis and Manipulation of Intracellular Signaling Cascades. Methods, 32/4:347-348.
Training                     Name                                        Current Position
1992 - 1995               Caretha Creasy, PhD        Oncology Early Development Leader, GSK
1993 - 1996               Diane Ambrose                   Clin. Res. Ctr. UMDNJ
1997 - 1998               Robert Louden                    Assoc. Teaching Professor, Dept. of Biology, Drexel University
1997 – 2002             Melissa Reeder                   Cell Pathways
1998 – 2005             Shrikrishna Dadke            VP, Biopharma, Vimta Labs Ltd, Hyderabad, India
2001 – 2006             Alexander Beeser             Asst. Prof. of Biology, Lyon College, Batesville, Arkansas
2002 – 2005             Elena Sorokina                   Sr. Research Scientist, Univ. of Pennsylvania
2000 – 2007             Zahara Jaffer                      Asst. Dir., Technology Licensing, U. Florida
2001 – 2007              Clemens Hofman             Clinical Supply Chain Manager, Fisher Clinical Services, Freiburg, Germany
2001 – 2008              Sophie Cotteret                Clinical cytogeneticist & molecular biologist, Institut de Cancérologie (GRCC), Villejuif, France
2008 – 2010              Almudena Pacheco          Sr. Scientist, Summation Bio, Lab Central
2006 – 2011               Jenny Yip                                Director of Business Development, PhenoVista Biosciences
2006 – 2014             Luis Arias Romero              Assoc. Prof., Nat’l Cancer Inst. Mexico
2008 – 2018             Hoi Yee (Betty) Chow      Assoc. Prof., Sichuan University, China
2008 – 2018            Maria Radu                             Sr. Scientist, Merck
2008 – 2013             Sayanti Saha                          Director, Partnerships and Transformation, Horizon Blue Cross Blue Shield of New Jersey
2008 – 2010            Christine Lightcap             Director, Integrated Product Development at PharmaLex
2012 – 2020              Tatiana Prudnikova          Investigator, GlaxoSmithKline
2014 – 2016              Daniela Araiza                     Research Associate, Fox Chase Cancer Center
2022 – present         “                                                 Assistant Research Professor
2018 – 2022              Cristina Uribe-Alvarez   Postdoctoral Associate
2022 – present         “                                                 Assistant Research Professor
2023 – present         Ramil Khusnutdinov       Postdoctoral Associate

Period                       Name                                 Current Position
1995 – 1999            Feng Liu                            Wyeth Pharmaceuticals
1999 – 2000          Olga Mitina                    University of Munich (Warmuth lab)
2003 – 2004         Mikhail Shepelev          Engelhardt Institute, Moscow
2006 – 2013          Dina Stepanova            Research Associate, Russian National Research Medical University, Moscow
2009 – 2016          Sonali Jalan                    Senior Scientist, Merck
2009 – 2014          Rachelle Kosoff            Principal Scientist, Translational Development, Century Therapeutics, LLC
2010 – 2014           Mollie Kelly                    Editor, Life Sciences, Cactus Communications
2011 – 2018           Galina Semenova         Postdoctoral Fellow, Fred Hutchinson Cancer Center
2018 – 2019           Cong Tao Zeng            Student, Sichuan University, China
2017 – 2023           Sofiia Karchugina       Graduate Student, RMSU, Chernoff Lab
2018 – 2023         Alexa Cannon              Graduate Student, Drexel University, Chernoff Lab
2018 – 2023    Konstantin Budagyan   Graduate Student, Drexel University, Chernoff Lab
2019 – present  Dorothy Benton          Graduate Student, Drexel University, Chernoff Lab
2019 – 2021        Gleb Abalakov               Postdoctoral Fellow, Temple University
1-2 high school and/or college student per year since 1992
1994 – 1997              Postdoctoral committee
1997 – present         Library committee
1997 – present         Seminars for medical oncology fellows (1x/yr)
1997 – present         Various promotion committees
1998 – present         Program Leader, Cancer Biology
1998 – 2000              Assisted Dr. Erica Golemis with setting up FCCC/RSMU sister-institution program
2001 – 2002              Leap-frog lecture series
2001 – present         FCCC/Ben Gurion University Program
2003 – present         FCCC/Drexel liaison
2003 – 2004              Vice President’s Advisory Board, Basic Science
2006 – 2008              Appointments & Promotions
2007 – present         ECOR Committee (Chair)
2009 – 2010              Search Committee (Chair), EPC Program
2010                           Faculty Senate Organizing Committee
2010 – 2011              Co-Leader, EPC Keystone Program
2012 – 2014              Temple/FCCC Science Integration Committee (Co-chair)
2015 – present         FCCC Internal Advisory Board
2013 – 2022              Nominations Committee (Chair)
1995                           “Signal Transduction” (Postdoctoral course at FCCC)
1997, 1998                “Signaling to the Cytoskeleton” (Physiology Course, Marine Biology Lab, Woods Hole
2001 – 2005              “Protein-Tyrosine Phosphatases” University of Pennsylvania BMB-550
2005 – present         “Protein Kinases” Drexel University SOM
2005 – present         “Lipid Kinases and Rho Proteins” Drexel University SOM
2013 – 2014              “Protein Kinases” University of Pennsylvania BMB-633
1978 - 1984               Medical Scientist Training Grant
1989 - 1991               PHS NRSA Postdoctoral Grant
1993 - 1998               NIH 1 R01 CA58836: “A Tumor Suppressing Protein Tyrosine Phosphatase”
1998 - 2003               NIH 1 R01 CA58836: “A Tumor Suppressing Protein Tyrosine Phosphatase”
2003 - 2008               NIH 1 R01 CA58836: “A Tumor Suppressing Protein Tyrosine Phosphatase”
1993 - 1996               Council for Tobacco Research, #3480: “Protein Tyrosine Phosphatase as Signal Transduction Probes”
1993 - 1996               W.W. Smith Foundation #C9201: “Protein Required for Transformation by the v-src Gene”
1996 - 1997               Institutional Pilot Project Grant: “Genetic strategies for Identifying Proteins Involved in Cell Polarity Control
1997 - 2001               NIH 1 R01 GM54168: “Regulation of p21-activated Kinases”
1997 - 2000               American Cancer Society, #CB-189: “Protein Kinases that Regulate Cell Shape and Polarity”   
2000 - 2002               American Cancer Society, #CB-189: “Protein Kinases that Regulate Cell Shape and Polarity”
2002 - 2004               American Cancer Society, #CB-189: “Protein Kinases that Regulate Cell Shape and Polarity “
1997- 2002                Leukemia Society of America (Scholar): #1005-98
2004 - 2006               PA Tobacco Formula Grant: “Assessing HER-2 Targets in Breast Cancer”
2005 - 2007               DOD: NR050032: “Identification of Protein Kinases Required for NF2 Signaling”
2007 - 2008               CTF: 2007B-05-003 “Synthetic lethal screen of FDA-approved drugs in NF2”
2005 - 2009               DOD: NF050030: “Analysis of p21-Activated Kinase Function in Neurofibromatosis Type 2” - $1,200,000 direct costs
2008 - 2010               Seed Grant: FCCC “Identification of key signaling enzymes required for embryonic stem cell pluripotent” - $150,000 direct costs
2009 - 2010               CTF: 2009A-05-002: “Use of Induced Progenitor Stem Cells to Treat NF1” - $30,000 direct costs
2008 - 2011               American Asthma Foundation: “p21-Activated Kinase-1 as a Novel Therapeutic Target in Asthma” - $750,000 direct costs
2007 - 2012               NIH 1 R01CA117884-8: “Function of p21-activated Kinases” - $1,050,000 direct costs
2010 - 2012               DOD NF093118: “Role of p21-Activated Protein Kinases in Neurofibromatosis 2 - $174,500 total costs (H.Y Chow, postdoctoral fellowship)
2011 - 2012               SPORE pilot project: “p21-activted kinases as therapeutic targets in ovarian cancer - $50,000 total costs
2008 - 2012               BSF: 2007038 “Spatio-temporal regulation of p21-actiated kinases (Pak) in a T cell model system” - $180,000 direct costs
2010 - 2012               DOD NF093039: “Use of Induced Progenitor Stem Cells to Treat NF1” - $150,000 direct costs
2010 - 2013               DOD BC097800: “Role of PTP1B in HER2 Signaling in Breast Cancer” - $523,000 total costs (S. Saha, postdoctoral fellowship)
2011 - 2013               CTF Preclinical Consortium Center: “Preclinical drug testing in NF2” - $250,000 total costs
2014 - 2017               DOD NF130108: “Testing the Role of p21-Activated Kinases in Schwannoma Formation Using a Novel Genetically Engineered Murine Model that Closely Phenocopies Human NF2 Disease” - $575,000 direct costs
2016 - 2017               Breast Cancer Alliance Exceptional Project Grant: “Dissecting a Breast Cancer Amplicon using CRISPR/Cas” - $100,000 direct costs
2015 - 2018               ACS 122275-IRG-92-027-18-IRG: “Institutional Research Grant” - $180,000 direct costs
2015 - 2020               NIH 1 R01 CA142928: “p21-Activated Kinases as New Therapeutic Targets in Neurofibromatosis Type 1” - $1,125,000 direct costs
2016 - 2021               NIH 1 R01 CA148805: “The Role of p21-Activated Kinases in Malignant Mesothelioma” - $1,200,000 direct costs
2018 - 2023               NIH 1 R01 CA227184: “Targeting the Rac1 Signaling Pathway in Malignant Melanoma” - $1,250,000 direct costs
2018 - 2020               Melanoma Research Foundation: “RAC1 mutant melanoma: models and therapeutics” - $200,000 direct costs
2020 - 2023               NIH 1 R01 NS066927 (Jun Li, PI): “Pathophysiology of Conduction Blocks in HNPP” (subcontract from Vanderbilt) - $66,000 direct costs
2016 - 2021               NIH-T32-CA009035-41 (PI: Chernoff): “Training Program in Postdoctoral Research”
2016 - 2023               P30 CA006927 (PI: Fisher): “Comprehensive Cancer Center Program at Fox Chase”
2022 - 2023               PA Breast Cancer Alliance (PI: Chernoff): “Identifying and targeting key driver genes within a breast cancer amplicon” - $50,000 direct costs
2022 - 2023               Children’s Tumor Foundation (PI: Chernoff): “Evaluation of a PAK1-selective PROTAC, alone and with Hippo inhibitors, as a targeted therapy in NF2” - $40,000 direct costs
1999 - 2005               Journal of Biological Chemistry, Editorial Board
2008 - 2019               Molecular Biology of the Cell, Editorial Board
2015 - present          Cancer Biological Therapy, Editorial Board
2020 - present          Cancers
2021 - present          Cancer Biology Section, Oncology Gateway, F1000 Research
2022 - present          Aging and Cancer Research & Treatment
*Frequent reviewer: Nature Cell Biology, Science Signaling, Molecular Cell, Current Biology, Journal of Cell Biology, Molecular Cellular Biology, Oncogene, and PNAS

1999 - 2000               Ad hoc reviewer for CDB-2 (now MBY-3)
1999 - 2000               ACS Cell Signaling and Metastasis
2002                           DOD NF panel A
2005                           The Leukemia and Lymphoma Society
1999 - 2002               Tobacco Related Disease Research Program, CA
2005 - 2007               Tobacco Related Disease Research Program, CA
2008-                          NIH R13 review panel
1998 & 2003             Program Project Grant - University of Virginia PPG “Signaling in time and Space”
2007                           Program Project Grant - University of North Carolina PPG “Biosensors for Sensitive Multiplex Analysis of Endogenous Proteins”
2007                           Program Project Grant - University of Wisconsin PPG “Low molecular weight GTPases in vascular biology”
2007                           Children’s Tumor Foundation - Drug Discovery Initiative Award (Co-chair)
2008 – 2011              New Jersey Commission on Cancer Research
2009 – present         AIRC - Italian Association for Cancer Research
2010                           Member, College of CSR Reviewers
2010 – 2012              DOD NFRP Integration panel
2013 – present         Fundación La Murato de TV3 (Spain)
2013                           Austrian Science Fund
2013 – present         La Caixa (Spain)
2013                           CCSG site visits: Masonic CCC, JAXCC
2015                           NIH Outstanding Investigators panel (R35)
2016                           AACR Basic Cancer Research Fellowships Scientific Review Committee
2016                           NIH Provocative Question (PQ6) panel
2018                           CCSG site visit: Hollings CC (MUSC)
2018                           NIDDK Board of Scientific Counselors Review
2019                           AACR Outstanding Investigator Award for Breast Cancer Research Selection Committee
2020                           Melanoma Research Foundation
2021                           DOD Neurofibromatosis, CET-1 panel
2021                           Chair, DOD Melanoma Research Program, CMB-2 panel
2022                           Children’s Tumor Foundation - Drug Discovery Initiative Award
2022                           Chair, DOD Neurofibromatosis, CET-1 panel
2022                           FWO (Fonds voor Wetenschappelijk Onderzoek) Vlaanderen, Belgium
2022                           Chair, DOD Melanoma Research Program, CMB-2 panel
2023                           AACR Small Molecule Therapeutic Agents Section of the Experimental Therapeutics Subcommittee of the Program Committee
2023                           CCSG Site visit: CINJ
2004 - 2011         Scientific Advisory Board: Nexgenix Pharmaceuticals
2008 - 2013         Genentech
2008 - 2011         Novartis              
2011 - 2016         NYU Cancer Institute EAB
2012 - 2014         Case Western Cancer Signaling Program EAB
2013 - 2017         Scientific Advisory Boards: Tarsa, Pharma-Arava, Enteris
2017 - present    External Advisory Board: U. Miami Epigenetics T32
2019 - 2020         Novo-Nordisk
2019 - present    Scientific Advisory Board: NF2 BioSolutions
2021 - present    BloodQ
2022 - present    Metastyx
(unrecorded prior to 1996)
March 1996               Clinical Research Institute of Montreal, Canada
April 1996                  Merck, West Point, PA
June 1996                 University of Pennsylvania, Philadelphia, PA
October 1996            Harvard Medical School, Boston, MA
October 1996            Washington University, St Louis, MO
December 1996       University of Pennsylvania, Philadelphia, PA
May 1997                  Cold Spring Harbor meeting on Tyrosine Phosphorylation - Invited Speaker
July 1997                   Marine Biology Lab, Woods Hole, MA
July 1997                   Astra Zeneca
October 1997            Wistar Institute, Philadelphia, PA
January 1998            Merck, West Point, PA
May 1998                  Johns Hopkins Medical School, Baltimore, MD
June 1998                 Massachusetts General Hospital Cancer Center, Boston, MA
July 1998                   Marine Biology Lab, Woods Hole, MA
August 1998              Salk Institute meeting on Tyrosine Phosphorylation - Invited Speaker
October 1998            University of Massachusetts, Amherst (Invited by Graduate Students)
November 1998        Indiana University School of Medicine (Invited by Graduate Students)
November 1998        Medical Research Institute, Indianapolis, IN
December 1998        Albert Einstein College of Medicine, NY, NY
January 1999            Institute of Molecular Genetics, Prague, Czech Republic
February 1999          National Cancer Institute, Bethesda, MD
February 1999          Astra Zeneca
March 1999               FASEB: Small GTPases, Santé Fe, NM - Invited Speaker
April 1999                  M.D. Anderson, Houston, TX
May 1999                  Onyx Pharmaceuticals, CA
July 1999                   Englehart Conference, Moscow, Russia. Invited Speaker
July 1999                   FASEB: Protein Kinases and Phosphorylation, Snowmass CO - Invited Speaker
November 1999        Harvard Medical School, Boston, MA
February 2000          MCP Hahnemann, Philadelphia, PA
April 2000                  The Picower Institute, NY
May 2000                  Medical College of Wisconsin, Milwaukee, WI
May 2000                  Onyx Pharmaceuticals, CA
May 2000                  Netherlands Cancer Institute, Amsterdam, Netherlands
May 2000                  Ludwig Institute for Cancer Research London, UK
May 2000                  Aventis Pharmaceuticals, Munich, Germany
July 2000                   FASEB: The Ras Superfamily of Small GTP-binding Proteins, Snowmass CO - Invited Speaker
March 2001               Albert Einstein College of Medicine, NY, NY
April 2001                  Indiana University, Indianapolis, IN
April 2001                  University of North Carolina, Chapel Hill NC
April 2001                  Morphochem Inc., Princeton, NJ
May 2001                  Sugen, Inc., S. San Francisco, CA
July 2001                   Ben Gurion University, Beer Sheva, Israel
August 2001              Gordon Conference: Mechanisms of Cell Signalling, Oxford UK - Invited Speaker
August 2001              Karolinska Institute, Huddinge, Sweden
November 2001        University of North Carolina, Chapel Hill, NC
March 2002               Mount Sinai School of Medicine, NY, NY
April 2002                  University Medical and Dental College of New Jersey, Newark, NJ
May 2002                  University of California, Los Angeles, CA
July 2002                   FASEB: Small G protein Networks in Cell Dynamics, Snowmass CO - Invited Speaker
October 2002            Stony Brook, NY
October 2002            Long Island Jewish Hospital, NY
October 2002            Cold Spring Harbor Laboratories, NY
June 2003                 Gordon Conference: Mechanisms of Cell Signaling, Ventura, CA - Invited Speaker
September 2003      Mt. Sinai School of Medicine; MD. Ph.D. retreat
December 2003        University of Cincinnati, Cincinnati, OH
February 2004          Mt. Sinai School of Medicine; MD. Ph.D. dinner, NY, NY
April 2004                  University of Florida, Tampa, FL
July 2004                   FASEB: Small G Protein Networks in Cell Dynamics, Snowmass CO - Invited Speaker
November 2004        Columbia University, NY, NY
December 2004        Roswell Park Cancer Institute, Buffalo, NY
February 2005          University of Pennsylvania, Philadelphia, PA
April 2005                  New York University, NY, NY
June 2005                 Gordon Conference: Mechanisms of Cell Signaling, Hong Kong, China - Vice-Chair
September 2005      University of Oklahoma, Oklahoma City, OK
November 2005        Banbury Conference: Barriers & Solutions in the Use of Mouse Models to Develop Therapeutic Strategies for NF1 and NF2 - Associated Tumors - Invited Speaker
December 2005        Wayne State, Michigan, Detroit, MI
May 2006                  University of California, Riverside, CA
May 2006                  Scripps University, La Jolla, CA
May 2006                  University of South Dakota, Sioux Falls, SD
May 2006                  Wyeth Pharmaceuticals, Pearl River, NY
July 2006                   FASEB: Small G Protein Networks in Cell Dynamics, Saxtons River VT - Vice-Chair
October 2006            University of Alberta, Edmonton, Canada
February 2007          Ben Gurion University, Beer-Sheva, Israel, Dozer Lecturer
February 2007          Tel Aviv University, Tel-Aviv, Israel
March 2007               University of Virginia, Charlottesville, VA
September 2007      Thomas Jefferson School of Medicine, Philadelphia, PA
September 2007      University of Gent, Gent, Belgium
September 2007      Gordon Conference: Mechanisms of Cell Signaling, Oxford, UK - Chair
September 2007      Oxford University, Oxford, UK
October 2007            Indiana University School of Medicine, Indianapolis, IN
November 2007        University of Illinois School of Medicine, Chicago, IL
April 2008                  Genentech, San Francisco, CA
May 2008                  Georgetown University, Washington, D.C.
May 2008                  University of Cincinnati, Cincinnati, OH
June 2008                 Weis Center for Research, Danville, PA
July 2008                   FASEB: Regulation and Function of Small GTPases, Saxtons River VT - Invited Speaker
September 2008      New York University, NY, NY
October 2008            University of Pennsylvania, Philadelphia, PA
January 2009            Novartis, Emeryville, CA
August 2009             Gordon Conference: Mechanisms of Cell Signaling, Oxford, UK - Invited Speaker
October 2009            Kansas State University, Manhattan, KS
October 2009            Lankenau Institute for Medical Research
March 2010               Novartis, Emeryville, CA
March 2010               Genentech, San Francisco, CA
March 2010               Case Western, Cleveland, OH
May 2010                  Mt Sinai School of Medicine, NY, NY
May 2010                  University of Virginia, Charlottesville, VA
May 2010                  American Asthma Foundation, San Francisco, CA
June 2010                 Neurofibromatosis Conference, Baltimore, MD - Session Chair
June 2010                 Russian Academy of Science conference: Control of Gene Expression, Moscow, Russia - Session Chair
July 2010                   FASEB: Protein Kinases and Phosphorylation, Snowmass, CO - Invited Speaker
October 2010            University of West Virginia, Morgantown, WV
May 2011                  Genentech, San Francisco, CA
June 2011                 FASEB: Regulation and Function of Small GTPases, Saxtons River, VT - Invited Speaker
November 2011        Case Western, Cleveland, OH
February 2012          Commonwealth Medical College, Scranton, PA
March 2012               Memorial Sloan Kettering Cancer Center, NY, NY
May 2012                  Genentech, San Francisco, CA
June 2012                 Neurofibromatosis Conference, New Orleans, LA - Invited Speaker
June 2012                 Rutgers University School of Medicine, Piscataway, NJ
July 2012                   University of Utah, Provo, UT (two lectures)
September 2012      University of North Carolina, Chapel Hill, NC
September 2012      Duke University, Durham, NC
October 2012            Temple University, Philadelphia, PA
December 2012        McGill University, Montreal, Canada
January 2013           Astra-Zeneca, Boston, MA
March 2013               New York University, MD/PhD retreat, Stowe, VT - Keynote Speaker
June 2013                 FASEB: Regulation and Function of Small GTPases, Snowmass, CO - Invited Speaker
July 2013                   Albert Einstein Medical School, NY, NY
September 2013      National Cancer Institute of Mexico, Mexico City (two lectures) - Distinguished Speaker
November 2013        PDDI Annual Drug Discovery Awards, Doylestown, PA - Keynote Presentation
December 2013        Temple University, Sol Sherry Thrombosis Center, Philadelphia, PA
March 2014               Perlmutter Cancer Center, NYU, NY, NY
April 2014                  AACR, San Diego, CA - Targeting Rho GTPases and Their Kinases Effectors - Educational Session Chair
May 2014                  Ohio State Cancer Center, Columbus, OH
May 2014                  University of Leuven, Leuven, Belgium
May 2014                  Karolinska Institute, Huddinge, Sweden
June 2014                 Neurofibromatosis Conference, Washington, DC - Invited Speaker
June 2014                 Biomedicine Research unit (UBIMED), Mexico City, Mexico - Plenary Lecture
January 2015            Oregon Health & Science University, Portland, SC
April 2015                  Temple University, Philadelphia, PA
June 2015                 FASEB: Regulation and Function of Small GTPases, Palm Beach, FL - Invited Speaker
January 2016            Medical University of South Carolina, Charleston, SC
February 2016          Temple University School of Medicine, Administrative Forum, Philadelphia, PA
February 2016          Yale University School of Medicine, New Haven, CT
March 2016               Yale University School of Medicine, Grand Rounds, New Haven, CT
May 2016                  University of North Carolina, Chapel Hill, NC
September 2016      Temple University School of Medicine, Translational Day Award Lecture
February 2017          University of Miami, Miami, FL
May 2017                  Frederick National Laboratory for Cancer Research, Frederick, MD
May 2017                  Puerto Rico INBRE and COBRE Scientific Symposium, San Juan, PR - Invited Speaker
June 2017                 FASEB: Regulation and Function of Small GTPases, Palm Beach, FL - Invited Speaker; Session Chair
August 2017              Albert Einstein Medical School, NY, NY
November 2017        Sidney Kimmel Cancer Center, Thomas Jefferson, Grand Rounds, Philadelphia, PA
February 2018          RISE program seminar, University of Puerto Rico, San Juan, PR
April 2018                  UBIMED, UNAM, Mexico City, Mexico
April 2018                  Instituto deQuimica, UNAM, Mexico City, Mexico
July 2018                   Biochemical Society: Small G proteins in cellular signaling and disease, Cambridge, UK - Invited Speaker
August 2018              Coriell Institute, Camden, NJ
September 2018      American Society for Biochemistry & Molecular Biology 2018, Frontiers in RAS Pathobiology and Drug Discovery Special Symposium, Stratton, VT - Invited Speaker
March 2019               UC Davis Cancer, Sacramento, CA
May 2019                  Fundacion Ramon Areces: The RAS superfamily and related pathways in healthy and disease, Santander, Spain - Invited Speaker
June 2019                 Simposium Avances Biomedicos en Cancer y Enfermedades Cronico Degenerativas XV ANIVERSARIO UNIDAD DE BIOMEDICINA Facultad de Estudios Superiores Iztacala, UNAM, Mexico City, Mexico - Invited Speaker
October 2019            1st Pak symposium, NY, NY - Keynote Speaker
November 2019        University of Pittsburgh, Pittsburgh, PA
January 2020            Sidney Kimmel Cancer Center, Annual Retreat, Philadelphia PA - Keynote Speaker
February 2021          Turning Point Therapeutics (via Zoom)
November 2021        Turning Point Therapeutics (via Zoom)
February 2022          MPM Capital (via Zoom)
April 2022                  Panel Speaker, Children’s Tumor Foundation NF2/SWN Workshop (via Zoom)
June 2022                 FASEB: Regulation and Function of Small GTPases, Saxtons River, Vermont - Invited Speaker
September 2022      Biochemical Society: Small G proteins in cellular signaling and disease, Liverpool, UK - Invited Speaker
November 2023        Mexican Society for Biochemistry: Signal Transduction, Ensenada Baja California - Keynote Speaker